Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617129 | 0.78 | KIF11 (0.44) | MAPTTSHRRAB9ACHRM2CHRM1 | |
| SCHEMBL6368657 | 0.74 | ALDH1A1 (0.42) | ALDH1A1MAPTCCR1EPHX2HPGD | |
| SCHEMBL6928586 | 0.70 | HDAC3 (0.54) | ALDH1A1CCR1EPHX2HPGDRAB9A | |
| SCHEMBL13348713 | 0.70 | EPHX1 (0.51) | ALDH1A1CCR1EPHX2HPGDRAB9A | |
| SCHEMBL9667392 | 0.68 | KIF11 (0.44) | ALDH1A1MAPTTSHRRAB9ACHRM2 | |
| SCHEMBL25464159 | 0.67 | HDAC1 (0.49) | ALDH1A1MAPTCCR1RAB9ACHRM2 | |
| SCHEMBL11582899 | 0.67 | CCR1 (0.53) | ALDH1A1CCR1EPHX2CNR1CNR2 | |
| SCHEMBL28033810 | 0.66 | MAPT (0.47) | MAPTCHRM2CHRM1CHRM3 | |
| SCHEMBL25464076 | 0.65 | MAPT (0.46) | ALDH1A1MAPTCCR1EPHX2HPGD | |
| SCHEMBL6946455 | 0.65 | SSTR1 (0.47) | CCR1HPGDRAB9ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | ALDH1A1 575/4885MAPT 694/4885CCR1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.